

**Avraham (Avi) Yacobi, Ph.D., M.Pharm.**

Dr. Avi Yacobi is an expert in pharmaceutical research and development and regulatory affairs. He has over 35 years of experience in the industry and in working with the U.S. Food and Drug Administration (FDA) and its counterparts abroad and other state and foreign regulatory agencies. He started his industrial career at American Critical Care and continued at American Cyanamid Company prior to joining Taro Pharmaceutical Industries (Taro) in 1994. Throughout his career, he was engaged in pharmaceutical R&D and in drug registration globally.

Most recently, Dr. Yacobi has served as the President of Taro Research Institute (TRI), a subsidiary of Taro Pharmaceutical Industries and President of R&D, Taro Pharmaceutical U.S. Inc. He worked at Taro for over 16 years during which time he built a very dynamic, strong and efficient R&D group, developed generic, branded generic and innovative products. The focus of the R&D group was largely topical semisolid products and other difficult to manufacture products, including controlled release dosage forms.

TRI developed chemical processes to synthesize active pharmaceutical ingredients (API), developed novel and generic pharmaceutical products, conducted extensive clinical and bioequivalence studies, filed INDs, DMFs, ANDAs and NDAs globally. As part of this effort, Dr. Yacobi was involved with all aspects of executive management, drug development, process validation, interaction with regulatory agencies, supported business development and prepared promotional materials for Taro's products.

Over his sixteen year career at Taro, the R&D group filed over 130 ANDA's, 35 DMF's and several 505b2 and 505b1 NDA's. During the same period, a large number of products were registered in EU countries, Canada, Israel and the rest of the world. TRI was actively engaged in developing branded and novel products including two new chemical entities in the CNS areas.

Presently, Dr. Yacobi works as an independent consultant, engaged in pharmaceutical product development at DOLE Pharma LLC and serves as a scientific advisor at BluPax Pharma and at Orenova Development Company. Dr. Yacobi also serves on the board of directors of PQRI, representing AAPS.